Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Person › Details

Walid Abi-Saab (Galapagos N.V. (Euronext + Nasdaq: GLPG))

Abi-Saab, Walid (Galapagos 201809 CMO)

	Organisation	Galapagos N.V. (Euronext + Nasdaq: GLPG)
	Group	Galapagos (Group)
	Product	drug discovery services
	Product 2	clinical research
	Source	Galapagos N.V.. (9/11/18). "Press Release: Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis". Foster City, CA & Mechelen.

Record changed: 2021-02-17

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Walid Abi-Saab

[1] Galapagos N.V.. (2/10/21). "Press Release: Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF". Foster City, CA & Mechelen....
[2] Galapagos N.V.. (11/5/20). "Press Release: OncoArendi and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis". Mechelen & Warsaw....
[3] Galapagos N.V.. (10/15/20). "Press Release: Galapagos and Servier Report Topline Results for ROCCELLA Phase 2 Clinical Trial with GLPG1972/S201086 in Knee Osteoarthritis Patients". Mechelen & Paris....
[4] Galapagos N.V.. (8/19/20). "Press Release: Galapagos Announces that Gilead Received a Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis". Mechelen....
[5] Galapagos N.V.. (1/13/20). "Press Release: Galapagos Completes Recruitment of PINTA Trial in Idiopathic Pulmonary Fibrosis". Mechelen....
[6] Galapagos N.V.. (10/10/19). "Press Release: Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis". Foster City, CA & Mechelen....
[7] Galapagos N.V.. (8/15/19). "Press Release: European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis". Foster City, CA & Mechelen....
[8] Galapagos N.V.. (5/29/19). "Press Release: Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)". Foster City, CA & Mechelen....
[9] Galapagos N.V.. (1/6/19). "Press Release: Galapagos Initiates NOVESA Phase 2a Trial in Patients with Systemic Sclerosis". Mechelen....
[10] Galapagos N.V.. (12/17/18). "Press Release: Galapagos Reports Initiation of ISABELA Phase 3 Program with GLPG1690 in Patients with Idiopathic Pulmonary Fibrosis (IPF)". Mechelen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]